Innoviva (INVA) Cash & Current Investments (2010 - 2026)
Innoviva's (INVA) quarterly Cash & Current Investments came in at $603.1 million in Q1 2026, up 89.0% YoY from $319.1 million in Q1 2025, and up 9.46% on a QoQ basis from $550.9 million in Q4 2025.
Analysis
Innoviva (INVA) Cash & Current Investments (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Cash & Current Investments data on file, last reported at $603.1 million in Q1 2026.
- Quarterly Cash & Current Investments rose 89.0% year-over-year to $603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $603.1 million (up 89.0% YoY) and the FY2025 annual result came in at $550.9 million, up 80.66% from the prior year.
- Cash & Current Investments climbed to $603.1 million in Q1 2026, from $550.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $603.1 million in Q1 2026 to a low of $144.0 million in Q1 2023.
- A 5-year average of $299.5 million and a median of $283.6 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 555.45% — and 2023, when it slumped 40.21%.
- Tracing INVA's Cash & Current Investments over 5 years: stood at $291.0 million in 2022, then sank by 33.51% to $193.5 million in 2023, then soared by 57.59% to $305.0 million in 2024, then soared by 80.66% to $550.9 million in 2025, then gained by 9.46% to $603.1 million in 2026.
- The last three Cash & Current Investments figures came in at $603.1 million (Q1 2026), $550.9 million (Q4 2025), and $476.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 579.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 579.06 Mn |
| Mar 31, 2026 | 611.93 Mn |
| Dec 31, 2025 | 566.67 Mn |
| Sep 30, 2025 | 533.10 Mn |
| Jun 30, 2025 | 497.73 Mn |
| Mar 31, 2025 | 446.88 Mn |
| Dec 31, 2024 | 412.50 Mn |
| Sep 30, 2024 | 260.63 Mn |
| Jun 30, 2024 | 217.00 Mn |
| Mar 31, 2024 | 178.36 Mn |
| Dec 31, 2023 | 193.51 Mn |
| Sep 30, 2023 | 180.00 Mn |
| Jun 30, 2023 | 173.03 Mn |
| Mar 31, 2023 | 144.05 Mn |
| Dec 31, 2022 | 291.05 Mn |
| Sep 30, 2022 | 301.07 Mn |
| Jun 30, 2022 | 283.58 Mn |
| Mar 31, 2022 | 216.80 Mn |
| Dec 31, 2021 | 201.53 Mn |
| Sep 30, 2021 | 135.12 Mn |